Clinical trials: Conduct Disorder
HIV Infections
A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)
The objective is to determine the effect of Isoprinosine (inosine pranobex) in homosexual male patients with AIDS related complex (ARC) in delaying the onset of AIDS.
- Trial name
- NCT00002060
- Testing
- Inosine pranobex
- Where
- United States
- Sponsor
- Newport Pharmaceuticals International
ADHD
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
- Trial name
- NCT07314333
- Testing
- Centanafadine, Methylphenidate, Lisdexamfetamine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bronchospasm, Activity/Exercise Induced Bronchospasm
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
During this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. Certain office visits will include physical exams, medical history review, exercise challenge test…
- Trial name
- NCT00118716
- Testing
- Fluticasone propionate/salmeterol, Fluticasone Propionate
- Where
- 50 sites in United States
- Volunteers
- 248 people
- Sponsor
- GlaxoSmithKline
Agitation Associated With, Alzheimer's Disease
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01862640
- Testing
- Brexpiprazole, OPC-34712
- Where
- 85 sites in United States, Croatia and 5 more
- Volunteers
- 433 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Haemophilia A, Haemophilia B
A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
The Hemophilia Growth and Development Study (HGDS) nearly 25 years ago showed haemophilia and HIV impacted brain development, thinking, and behaviour in children and adolescents.
- Trial name
- eTHINK (NCT03660774)
- Testing
- No treatment given
- Where
- 22 sites in United States
- Volunteers
- 563 people
- Sponsor
- Novo Nordisk A/S
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a two-arm, parallel, randomized, double-blind, placebo-controlled Phase 4 multicenter trial to compare the whole day efficacy of atomoxetine versus placebo in children aged 6 through 12 years with…
- Trial name
- NCT00546910
- Testing
- Atomoxetine
- Where
- 16 sites in Germany
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Pulmonary Hypertension
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
This pilot, non-interventional, company-sponsored, multi-center study documents observational data on patients under routine treatment of Pulmonary Arterial Hypertension (PAH) with inhaled iloprost (using I-Neb device for the…
- Trial name
- COMPHI (NCT01894035)
- Testing
- Iloprost (Ventavis, BAYQ 6256)
- Where
- Portugal
- Volunteers
- 13 people
- Sponsor
- Bayer
Renal Insufficiency
Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction.
- Trial name
- NCT01658514
- Testing
- Met DR, Met XR
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Elcelyx Therapeutics, Inc.
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Psychological Stress, Sleep Disturbance
Sleep More, Stress Less: 90-Day Trial of Neuralli Mood
This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in…
- Conditions
- Psychological Stress, Sleep Disturbance, Anxiety Symptoms, Depressive Symptoms
- Trial name
- NM90 (NCT07717385)
- Testing
- Neuralli Mood
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Efforia, Inc
Attention-Deficit/Hyperactivity Disorder (ADHD)
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
The purpose of this study is to investigate the safety and efficacy of an investigational treatment for Attention Deficit Hyperactivity Disorder (ADHD) when compared to placebo.
- Trial name
- NCT00475735
- Testing
- MK0249, Concerta (methylphenidate)
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit and Hyperactivity Disorder
A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01174355
- Testing
- ND0801
- Where
- 2 sites in Israel
- Volunteers
- 40 people
- Sponsor
- NeuroDerm Ltd.
Hemophilia A, Prophylaxis of Bleeding
An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.
This is an observational study in which data from people with hemophilia A who decide on their own or by recommendation of their doctors to take Jivi are collected and studied.
- Trial name
- JOIHA (NCT05643560)
- Testing
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Bayer
Attention-Deficit/Hyperactivity Disorder
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.
- Trial name
- NCT00391729
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abbott
Major Depressive Disorder
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00707980
- Testing
- Vortioxetine
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 836 people
- Sponsor
- Takeda
Job Stress, Distress, Emotional
Depression Return to Work Intervention
This study is a randomized controlled trial to test the effectiveness of a mobile app-based program aimed to help individuals with unemployment-related emotional distress return to work.
- Trial name
- DRIVEN (NCT06026280)
- Testing
- DRIVEN Application, Career Resources
- Where
- United States
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Inspiration at Work
COPD, Smoking
Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.
The purpose of this study is to demonstrate the slowing of the disease progression including the improvement of Chronic Obstructive Pulmonary Disease (COPD) symptoms in smoking subjects with mild to moderate COPD and a history of…
- Conditions
- COPD, Smoking, Tobacco Use
- Trial name
- NCT05569005
- Testing
- THS use, Cigarette, Smoking Abstinence
- Where
- 170 sites in United States, Bulgaria and 6 more
- Volunteers
- 715 people
- Sponsor
- Philip Morris Products S.A.
Depressive Disorder, Major
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD-1 (NCT07412756)
- Testing
- Brenipatide
- Where
- 181 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels
The purpose of this study is to evaluate the dose strength equivalence of to-be-marketed (TBM) centanafadine (CTN) once daily (QD) extended release (XR) when administered as 2 capsules of 164.4 milligrams (mg) or as a single…
- Trial name
- NCT07253441
- Testing
- CTN XR (TBM), CTN SR, CTN XR (Clin)
- Where
- 2 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06786624
- Testing
- NBI-1065845
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.